In six months, Solidarity, the world’s largest randomized control trial of treatments for COVID-19, has generated conclusive evidence. Interim results from the trial, coordinated by the World Health Organization (WHO), indicate that remdesivir, hydroxychloroquine, lopinavir / ritonavir, and interferon therapies have had little or no effect on 28-day mortality, as well as on evolution of patients hospitalized for COVID-19.
The first COVID traffic light in the EU: almost all of Europe, red
The study, which spans more than 30 countries, examined the effects of these treatments on overall mortality, initiation of ventilation, and length of hospital stay in hospitalized patients. Other uses of the drugs, for example in the treatment of out-of-hospital patients or for the prevention of disease, would have to be examined in different trials.
According to the WHO in a statement issued Thursday night, the progress made by Solidarity shows that large international trials are possible, even during a pandemic, and offers the promise of responding quickly and reliably to critical public health questions. related to therapies.
Trial results are being reviewed for publication in a medical journal and are available as preprint in the preprint repository medRxiv.
Evaluation of other promising options
WHO suspended trials with hydroxychloroquine and lopinavir / ritonavir in June after they were shown to be ineffective, but the global platform Solidarity will be able to evaluate promising new treatment options, with nearly 500 hospitals as trial centers, the organization notes.
The WHO program is considering for evaluation new antiviral drugs, immunomodulators and monoclonal antibodies against the effects of SARS CoV-2.
On the other hand, earlier this month, the company Gilead indicated that their drug remdesivir shortened recovery time from COVID-19 by five days compared to placebo patients in a study of 1,062 patients, which was published in New England Journal of Medicine. The firm has not yet officially commented on the WHO decision.